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ABSTRACT
Objective: The present study was aimed to evaluate antihyperglycemic and antihyperlipidemic activities of methanolic extract of Aristolochia 
bracteolata (MEAB) against dexamethasone-induced diabetic rat model.
Methods: Methanolic extract was prepared by soxhlet extraction and was evaluated for antihyperglycemic and antihyperlipidemic activity using 
dexamethasone-induced model. The MEAB was administered orally at a dose of 200 and 400 mg/kg body weight glibenclamide was used as standard 
drug. On 0th and 11th day, blood was collected by retro-orbit plexus.
Results: In this model blood glucose levels were determined on 0th and 11th days and MEAB significantly reduced the blood glucose levels in diabetic 
rats. The effect of MEAB on serum lipid profile such as total cholesterol (TC), triglycerides (TGs), low-density lipoprotein (LDL), very LDL (VLDL), 
and high-density lipoprotein (HDL) was also measured on the 11th day in the diabetic rats. Significant reduction in TC, TGs, LDL, and VLDL levels and 
improvement in HDL level were observed in diabetic rats.
Conclusion: From the results, it was found that the MEAB possess antihyperglycemic and antihyperlipidemic activities.
Keywords: Aristolochia bracteolata, Glibenclamide, Antihyperglycemic, Antihyperlipidemic, Dexamethasone.
INTRODUCTION
Diabetes mellitus is a chronic disease caused by inherited or acquired 
deficiency in the production of insulin by the pancreas or by the 
ineffectiveness of the produced insulin. Such a deficiency results 
in increased concentrations of glucose in the blood, which in turn 
damage many of the body’s systems, in particular, the blood vessels and 
nerves [1]. Over 90% of patients with diabetes have Type 2 diabetes; the 
remainder has Type 1 diabetes. According to the recent data from the 
World Health Organization and International Diabetes Federation, the 
number of people affected with diabetes worldwide has increased 
dramatically over recent years. Currently, there are over 366 million 
diabetics worldwide, and this is likely to increase to 552 million more 
by the year 2030 [2,3]. Diabetes mainly characterized by hyperglycemia, 
ketoacidosis, and hypertriglyceridemia. The characteristic symptoms 
of diabetes are polyuria, polydipsia, polyphagia, and unexpected 
weight loss [4]. Abnormalities in lipid profile are one of the most 
common complications in diabetes mellitus, which is found in about 
40% of diabetes patients [5]. Diabetes induction causes an increase 
in cholesterol, triglycerides (TGs), low-density lipoprotein (LDL), and 
very LDL (VLDL) [6]. The levels of serum lipids are usually elevated in 
diabetes mellitus, and such an elevation represents the risk factor for 
coronary heart disease [7]. Management of diabetes without any side 
effect is still a challenge to the medical community.
The ethnomedicine and ethnopharmacology remedies have gained 
popularity among the people of developing countries, being safe, 
effective, and inexpensive [8]. Aristolochia bracteolata belongs to 
the family Aristolochiaceae [9]. A literature survey revealed that 
methanolic extract of whole plant of A. bracteolata is endowed 
with various chemical components such as phenolic compounds, 
flavonoids, triterpenoids, alkaloids, steroids, cardiac glycosides, 
saponins, aristolochic acid-A, and aristolochic acid-D. A. bracteolata 
is an herbal medicine for the treatment of various diseases such as 
gastric stimulant, anti-inflammatory agents, antifungal, antibacterial 
activity, and cancer [10].
The present study is carried out to investigate the effect of oral 
administration of methanolic extract of whole plant of A. bracteolata 




Dexamethasone was purchased from SVR Chemicals Ltd., (Hyderabad). 
Glucose kit and lipid profile kits were purchased from K. K. Diagnostics 
(Hyderabad). All other chemicals were obtained from the Dwarakamai 
Enterprises (Hyderabad).
Animals
Adult Wistar albino rats (150-200 g) were used for the present study. 
They were kept in polypropylene cages at 25±2°C, with relative 
humidity 45-55% under 12 hrs light and dark cycles. All the animals 
were acclimatized to the laboratory conditions for a week before use. 
They were fed with standard animal feed and water ad libitum. All 
the pharmacological experimental protocols were approved by the 
Institutional Animal Ethics Committee (IAEC) (Reg. No. 1175/PO/
Ere/S/08/CPCSEA), Gokaraju Rangaraju College of Pharmacy.
Preparation of extract
The plant A. bracteolata was collected in January 2016 from the 
Nallamala Forest region, Velugodu, Kurnool district. The procured 
plant materials were authenticated by a botanist. The whole plant was 
washed, dried at room temperature in the dark and then, finely grind 
to a powder. Then, the powder was extracted with the methanol in the 
ratio of 1:6 by simple distillation technique. The solvent was completely 
removed under reducing pressure, and a semisolid mass (yield: 9.4%, 
w/w) was obtained and stored for further study.
Preliminary phytochemical analysis
The preliminary phytochemical studies were performed for testing 
different chemical groups present in MEAB. Phytochemical screening 
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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gave positive results for phenolic compounds, flavonoids, triterpenoids, 
alkaloids, steroids, cardiac glycosides, and saponins [11].
Acute toxicity study
The acute oral toxicity [12] study was carried out as per the guidelines 
set by the Organization for Economic Co-operation and Development, 
the study was approved by the IAEC. No mortality and no signs 
of toxicity were found even after administration of a limit dose of 
2000 mg/kg body weight of extract; hence, 1/10th of the dose was taken 
as effective dose. Two doses, 200 and 400 mg/kg were selected for the 
present study to evaluate antihyperglycemic and antihyperlipidemic 
activity.
Dexamethasone-induced diabetic rat model
Diabetes was induced in healthy Wistar albino rats using dexamethasone 
at a dose of 10 mg/kg, body weight subcutaneous (s.c) for 10 days. 
Treatment was continued for 10 consecutive days with dexamethasone. 
The animals were randomly divided into five groups of six animals 
in each group. Group - I received saline (normal control), Group - II 
received dexamethasone 10 mg/kg, s.c (diabetic control), Group - III 
received dexamethasone 10 mg/kg, s.c and MEAB (200 mg/kg body 
weight), Group - IV received dexamethasone 10 mg/kg, s.c and MEAB 
(400 mg/kg body weight), and Group - V dexamethasone 10 mg/kg, s.c 
and glibenclamide (0.5 mg/kg). On the 11th day, blood was withdrawn 
from the animals and subjected for the analysis of blood glucose and 
all biochemical parameters such as total cholesterol (TC), TG, LDL, 
and VLDL and high-density lipoprotein (HDL) levels. The levels of the 
biochemical parameters in the treated groups were compared with that 
of diabetic control group [13].
Statistical analysis
All results were expressed as the mean±standard error mean. The 
results were analyzed for statistical significance by one-way ANOVA 




The preliminary phytochemical screening of the A. bracteolata showed 
the presence of phenolic compounds, flavonoids, triterpenoids, 
alkaloids, steroids, cardiac glycosides, and saponins.
Dexamethasone-induced diabetic rat model
The parameters such as body weight, blood glucose level, and 
lipid profile parameters of normal control group; diabetic control 
group, standard group (glibenclamide 0.5 mg/kg), and MEAB were 
summarized in Tables 1-3.
Effect of extract on body weight
The body weight of the normal and treated groups significantly differ 
from diabetic control on the 11th day shown in Table 1. The treated 
groups of animal body weight maintained throughout the experiment 
compare to diabetic control.
Effect of extract on blood glucose level
Blood glucose level was found to be increased in dexamethasone-
induced diabetic rats significantly when compared to control. The MEAB 
and standard drug treated groups had shown a significant decrease 
in blood glucose level when compared to diabetic control group. The 
results were tabulated in the Table 2, respectively.
Effect of extract on blood lipid profile 
The diabetes-induced hyperlipidemia was reversed significantly 
when compared to diabetic control which was depicted in the Table 3. 
A significant percentage reduction of TC level, LDL, TG, and VLDL in 
extract treated group was significant when compared to diabetic group. 
However, HDL levels increased with treatment of extract and standard 
group, respectively.
DISCUSSION
Dexamethasone is a potent glucocorticoid. Glucocorticoids are widely 
used therapeutic tools, particularly in treatment for anti-inflammatory 
and immunomodulatory purposes. Side effects of glucocorticoid 
treatment include steroid diabetes. Glucocorticoid-induced 
hyperglycemia is partially due to increased hepatic glucose production 
and insulin resistance of peripheral tissues. Moreover, glucocorticoids 
are known to inhibit insulin secretion.
Glibenclamide has been used for many years to treat diabetes to 
stimulate insulin secretion from pancreatic β-cells. In general diabetic 
rats show lower body weight, high blood glucose, and lipid levels as 
compared to normal rats. The present data indicated that MEAB at 
200 and 400 mg/kg significantly reduced the elevated fasting blood 
glucose levels and increased body weight in a dose-dependent manner 
in diabetic animals.
The possible mechanism by which MEAB reduced hypoglycemic 
action might be due to the presence of phenolic and flavonoids. These 
phytochemical constituents might be increasing either the pancreatic 
secretion of insulin from β-cells of islets of Langerhans or increased 
peripheral utilization of glucose [13,14]. 
Lipids play a vital role in the pathogenesis of diabetes mellitus. 
The levels of serum lipids are usually elevated in diabetes cases, 
and such an elevation represents the risk factor of coronary heart 
disease. High levels of TC and more importantly LDL-cholesterol 
in blood are major coronary risk factor [15]. The abnormal high 
concentration of serum lipids in the diabetic subjects is due, mainly 
to the increase in the mobilization of free fatty acids from the 
peripheral fat depots. Acute insulin deficiency initially causes an 
increase in free fatty acid mobilization from adipose tissue. The most 
common lipid abnormalities in diabetes are hypertriglyceridemia and 
hypercholesterolemia.
Table 1: Effect of MEAB on body weight by 
dexamethasone-induced diabetic rats
Group Treatment Body weight (g)
mean±SEM
0th day 11th day
I Normal control 166.5±2.125 176.1±2.358
II Diabetic control 165.5±2.109 147.3±2.951
III MEAB200 mg/kg 168.6±1.926 172.3±1.498*
IV MEAB400 mg/kg 169.8±1.661 174.5±1.565**
V Glibenclamide 0.5 mg/kg 167.1±1.887 172.8±1.990**
Values are mean±SEM, n=6 when compared with control *p<0.05, **p<0.01. 
SEM: Standard error mean, MEAB: Methanolic extract of Aristolochia 
bracteolata
Table 2: Antihyperglycemic activity of MEAB on 
dexamethasone-induced diabetic rats
Group Treatment Blood glucose levels  
(mg/dL)
mean±SEM
0th day 11th day
I Normal control 84.5±2.446 85.1±2.482
II Diabetic control 84.6±2.859 235.8±1.740
III MEAB (200 mg/kg) 84.8±3.048 124.5±1.231*
IV MEAB (400 mg/kg) 87.6±2.304 116.6±1.115**
V Glibenclamide (0.5 mg/kg) 86.3±3.639 105.1±1.351*
Values are mean±SEM, n=6 when compared with control *p<0.05, **p<0.01. 
SEM: Standard error mean, MEAB: Methanolic extract of Aristolochia 
bracteolata
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The MEAB at 200 and 400 mg/kg significantly reduced the elevated 
levels of TC, TGs, LDL, and VLDL and also increases the HDL levels 
in a dose-dependent manner in diabetic animals. The presence 
of phytochemical constituents such as phenolic, flavonoids, and 
triterpenoids may be responsible for the activity. These phytochemicals 
might have decreased cholesterol genesis and blood glucose levels [16].
CONCLUSION
The results of the present investigation are quite encouraging on oral 
administration of MEAB at a dose of 200 and 400 mg/kg body weight 
for 11 days in dexamethasone-induced diabetic rats. There was a 
significant decrease in elevated blood glucose levels when compared 
with diabetic control group. MEAB has also lowered the TC, TGs, LDL, 
and VLDL levels and increased the levels of HDL when compared to that 
of the diabetic control group in a dose-dependent manner. The present 
study revealed that MEAB possesses significant antihyperglycemic and 
antihyperlipidemic activity. However, further studies are required to 
confirm the exact mechanism of action and to isolate the phytochemical 
constituents responsible for these activities.
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Table 3: Antihyperlipidemic activity of MEAB on dexamethasone-induced diabetic rats
Group Treatment Lipid profile (mg/dL)
TC TG HDL LDL VLDL
I Normal control 92.5±1.384 74.16±1.327 37.50±1.945 40.16±2.194 14.83±0.265
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Values are mean±SEM, n=6 when compared with control *p<0.05, **p<0.01. SEM: Standard error mean, MEAB: Methanolic extract of Aristolochia bracteolate, TC: Total 
cholesterol, TG: Triglyceride, LDL: Low-density lipoprotein, VLDL: Very low-density lipoprotein, HDL: High-density lipoprotein
